|
|
|
| Correlation between Serum Levels of Chemokine CCL5 and Metalloproteinase MMP-9 and Postoperative Recurrence of Human Non-small Cell Lung Cancer |
| XUE Li-ying, ZHANG Meng, WANG Jue,et al |
| Department of Medical Oncology, People's Hospital of Inner Mongolia Autonomous Region, Inner Mongolia Huhhot 010017 |
|
|
|
|
Abstract 【Objective】To study the expression of chemokine CCL5 and MMP-9 in serum of human non-small cell lung cancer and their relationship with the postoperative recurrence. 【Methods】A prospective cohort study was conducted to investigate the serum levels of CCL5 and MMP-9 in 103 patients with NSCLC. Serum samples of all patients were collected at 3 months after operation. Serum samples of 20 healthy subjects were collected to detect the levels of CCL5 and MMP-9 as well. The patients were divided into the high level group and low level group of CCL5 and MMP-9 based on the median level of serum CCL5 and MMP-9 at 3 months postoperation. After two years of follow-up, the difference in recurrence rates between high-level group and low-level group was observed, and the correlation between level of CCL5 and MMP-9 and postoperative recurrence rate was analyzed. 【Results】The recurrence rate of CCL5 high-level group was 53.12% (17/32), which was significantly higher than that of CCL5 low-level group (29.58%, 21/71). The difference was statistically significant (P<0.05). The recurrence rate of MMP-9 high-level group was 46.67% (14/30), which was higher than that of MMP-9 low level group (32.88%, 24/73). The difference was statistically significant (P<0.05).The Cox regression analysis showed that the high levels of serum CCL5 and MMP-9 after three months of operation were correlated to the recurrence of NSCLC (P<0.05). No other indexes were not associated with postoperative recurrence (P>0.05). 【Conclusion】The abnormal elevated levels of serum chemokine CCL5 and MMP-9 may play an important role in the occurrence and development of NSCLC. Detecting the changes of serum CCL5 and MMP-9 levels after operation may be helpful for early warning of tumor recurrence.
|
|
Received: 27 March 2019
|
|
|
|
|
|
[1] 姚晓军,刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学,2014,22(8):1982-1986.
[2] 刘一胜,李小平,鲍方,章月安,等. 亚肺叶切除与肺叶切除对T1a,b N0M0期非小细胞肺癌预后的影响[J]. 海军医学杂志,2019,40(3):233-236.
[3] 吕晓丹,李瑶,李航,等.CCL5/CCR5生物学轴在肿瘤中作用的研究进展[J].现代生物医学进展,2017,17(19):3780-3782.
[4] 袁静萍,陈创,袁修学,等.乳腺癌中VEGF和MMP9的免疫组织化学表达及其与肿瘤转移复发的关系[J].中国组织化学与细胞化学杂志,2016,25(5):431-436.
[5] Shimada Y. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer[J]. Chest, 2013, 143(6):1626-1634.
[6] Wu CY.Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection[J]. Medicine, 2015, 94(45):e2013.
[7] 徐安平. 非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J]. 湖南师范大学学报(医学版),2018,15(3):129-132.
[8] 丁海霞.肿瘤相关巨噬细胞和CCL5在胃癌中的表达及其相关性研究[J].中国免疫学杂志,2016,32(1):74-78.
[9] 朱永云.乳腺癌CC类趋化因子5表达与上皮间质转化的相关性及其意义[J].中国肿瘤,2016,25(4):314-318.
[10]黎进,马炬明. 基质金属蛋白酶-2、9在胃癌中的研究进展[J]. 中国肿瘤,2015,24(05):403-407.
[11]郑红芳,丁厚中,李巧星,等. 肾癌组织中HMGB1、MMP9的表达与临床分期、预后的相关性研究[J]. 中国现代医学杂志,2016,26(22):28-33.
[12]张颖,黄卫锋. 趋化因子CCL5及其受体与自身免疫性疾病的研究进展[J]. 临床和实验医学杂志,2016,15(21):2175-2177. |
|
|
|
2019, Vol. 36 
